Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia

E. M. Mortensen, M. J. Pugh, L. A. Copeland, Marcos Restrepo, J. E. Cornell, Antonio R Anzueto, Jacqueline A Pugh

Research output: Contribution to journalArticle

95 Citations (Scopus)

Abstract

Recent studies suggest that statins and angiotensin-converting enzyme (ACE) inhibitors may have beneficial effects for some types of infections. The present study aimed to examine the association of outpatient use of these medications on 30-day mortality for subjects aged >65 yrs and hospitalised with community-acquired pneumonia. A retrospective national cohort study was conducted using the Department of Veterans Affairs administrative data including subjects aged ≥65 yrs hospitalised with community-acquired pneumonia, and having ≥1 yr of prior Veterans Affairs outpatient care. In total, 8,652 subjects were identified with a mean age of 75 yrs, 98.6% were male, and 9.9% of subjects died within 30 days of presentation. In this cohort, 18.1% of subjects were using statins and 33.9% were using ACE inhibitors. After adjusting for potential confounders, current statin use (odds ratio (OR) 0.54, 95% confidence interval (CI) 0.42-0.70) and ACE inhibitor use (OR 0.80, 95% CI 0.68-0.89) were significantly associated with decreased 30-day mortality. Use of statins and angiotensin-converting enzyme inhibitors prior to admission is associated with decreased mortality in subjects hospitalised with community-acquired pneumonia. Randomised controlled trials are needed to examine whether the use of these medications in patients hospitalised with community-acquired pneumonia may be beneficial. Copyright

Original languageEnglish (US)
Pages (from-to)611-617
Number of pages7
JournalEuropean Respiratory Journal
Volume31
Issue number3
DOIs
StatePublished - Mar 2008

Fingerprint

Hydroxymethylglutaryl-CoA Reductase Inhibitors
Angiotensin-Converting Enzyme Inhibitors
Pneumonia
Mortality
Veterans
Odds Ratio
Confidence Intervals
Ambulatory Care
Cohort Studies
Outpatients
Randomized Controlled Trials
Infection

Keywords

  • 3-Hydroxl-3-methyl-glutaryl-CoA reductase inhibitor
  • Angiotensin-converting enzyme inhibitor
  • Mortality
  • Pneumonia

ASJC Scopus subject areas

  • Pulmonary and Respiratory Medicine
  • Medicine(all)

Cite this

Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. / Mortensen, E. M.; Pugh, M. J.; Copeland, L. A.; Restrepo, Marcos; Cornell, J. E.; Anzueto, Antonio R; Pugh, Jacqueline A.

In: European Respiratory Journal, Vol. 31, No. 3, 03.2008, p. 611-617.

Research output: Contribution to journalArticle

Mortensen, E. M. ; Pugh, M. J. ; Copeland, L. A. ; Restrepo, Marcos ; Cornell, J. E. ; Anzueto, Antonio R ; Pugh, Jacqueline A. / Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia. In: European Respiratory Journal. 2008 ; Vol. 31, No. 3. pp. 611-617.
@article{c352928f4dbc4ead9b39f0ad5af5e6d3,
title = "Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia",
abstract = "Recent studies suggest that statins and angiotensin-converting enzyme (ACE) inhibitors may have beneficial effects for some types of infections. The present study aimed to examine the association of outpatient use of these medications on 30-day mortality for subjects aged >65 yrs and hospitalised with community-acquired pneumonia. A retrospective national cohort study was conducted using the Department of Veterans Affairs administrative data including subjects aged ≥65 yrs hospitalised with community-acquired pneumonia, and having ≥1 yr of prior Veterans Affairs outpatient care. In total, 8,652 subjects were identified with a mean age of 75 yrs, 98.6{\%} were male, and 9.9{\%} of subjects died within 30 days of presentation. In this cohort, 18.1{\%} of subjects were using statins and 33.9{\%} were using ACE inhibitors. After adjusting for potential confounders, current statin use (odds ratio (OR) 0.54, 95{\%} confidence interval (CI) 0.42-0.70) and ACE inhibitor use (OR 0.80, 95{\%} CI 0.68-0.89) were significantly associated with decreased 30-day mortality. Use of statins and angiotensin-converting enzyme inhibitors prior to admission is associated with decreased mortality in subjects hospitalised with community-acquired pneumonia. Randomised controlled trials are needed to examine whether the use of these medications in patients hospitalised with community-acquired pneumonia may be beneficial. Copyright",
keywords = "3-Hydroxl-3-methyl-glutaryl-CoA reductase inhibitor, Angiotensin-converting enzyme inhibitor, Mortality, Pneumonia",
author = "Mortensen, {E. M.} and Pugh, {M. J.} and Copeland, {L. A.} and Marcos Restrepo and Cornell, {J. E.} and Anzueto, {Antonio R} and Pugh, {Jacqueline A}",
year = "2008",
month = "3",
doi = "10.1183/09031936.00162006",
language = "English (US)",
volume = "31",
pages = "611--617",
journal = "Acta tuberculosea Scandinavica",
issn = "0903-1936",
publisher = "European Respiratory Society",
number = "3",

}

TY - JOUR

T1 - Impact of statins and angiotensin-converting enzyme inhibitors on mortality of subjects hospitalised with pneumonia

AU - Mortensen, E. M.

AU - Pugh, M. J.

AU - Copeland, L. A.

AU - Restrepo, Marcos

AU - Cornell, J. E.

AU - Anzueto, Antonio R

AU - Pugh, Jacqueline A

PY - 2008/3

Y1 - 2008/3

N2 - Recent studies suggest that statins and angiotensin-converting enzyme (ACE) inhibitors may have beneficial effects for some types of infections. The present study aimed to examine the association of outpatient use of these medications on 30-day mortality for subjects aged >65 yrs and hospitalised with community-acquired pneumonia. A retrospective national cohort study was conducted using the Department of Veterans Affairs administrative data including subjects aged ≥65 yrs hospitalised with community-acquired pneumonia, and having ≥1 yr of prior Veterans Affairs outpatient care. In total, 8,652 subjects were identified with a mean age of 75 yrs, 98.6% were male, and 9.9% of subjects died within 30 days of presentation. In this cohort, 18.1% of subjects were using statins and 33.9% were using ACE inhibitors. After adjusting for potential confounders, current statin use (odds ratio (OR) 0.54, 95% confidence interval (CI) 0.42-0.70) and ACE inhibitor use (OR 0.80, 95% CI 0.68-0.89) were significantly associated with decreased 30-day mortality. Use of statins and angiotensin-converting enzyme inhibitors prior to admission is associated with decreased mortality in subjects hospitalised with community-acquired pneumonia. Randomised controlled trials are needed to examine whether the use of these medications in patients hospitalised with community-acquired pneumonia may be beneficial. Copyright

AB - Recent studies suggest that statins and angiotensin-converting enzyme (ACE) inhibitors may have beneficial effects for some types of infections. The present study aimed to examine the association of outpatient use of these medications on 30-day mortality for subjects aged >65 yrs and hospitalised with community-acquired pneumonia. A retrospective national cohort study was conducted using the Department of Veterans Affairs administrative data including subjects aged ≥65 yrs hospitalised with community-acquired pneumonia, and having ≥1 yr of prior Veterans Affairs outpatient care. In total, 8,652 subjects were identified with a mean age of 75 yrs, 98.6% were male, and 9.9% of subjects died within 30 days of presentation. In this cohort, 18.1% of subjects were using statins and 33.9% were using ACE inhibitors. After adjusting for potential confounders, current statin use (odds ratio (OR) 0.54, 95% confidence interval (CI) 0.42-0.70) and ACE inhibitor use (OR 0.80, 95% CI 0.68-0.89) were significantly associated with decreased 30-day mortality. Use of statins and angiotensin-converting enzyme inhibitors prior to admission is associated with decreased mortality in subjects hospitalised with community-acquired pneumonia. Randomised controlled trials are needed to examine whether the use of these medications in patients hospitalised with community-acquired pneumonia may be beneficial. Copyright

KW - 3-Hydroxl-3-methyl-glutaryl-CoA reductase inhibitor

KW - Angiotensin-converting enzyme inhibitor

KW - Mortality

KW - Pneumonia

UR - http://www.scopus.com/inward/record.url?scp=42949123466&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=42949123466&partnerID=8YFLogxK

U2 - 10.1183/09031936.00162006

DO - 10.1183/09031936.00162006

M3 - Article

C2 - 17959631

AN - SCOPUS:42949123466

VL - 31

SP - 611

EP - 617

JO - Acta tuberculosea Scandinavica

JF - Acta tuberculosea Scandinavica

SN - 0903-1936

IS - 3

ER -